Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Barr Fluoxetine Goal: 80% Generic Penetration In First Six Months

  • News

Executive Summary

Barr hopes to achieve 80% generic substitution for Lilly's Prozac within the first six months after launch of its generic 20 mg fluoxetine capsules.

You may also be interested in...



AstraZeneca Mulls AaiPharma Omeprazole Patent; Will Not List Two Others

AstraZeneca is expected to make a decision on whether to list an aaiPharma patent covering omeprazole in the "Orange Book" by the end of the month.

AstraZeneca Mulls AaiPharma Omeprazole Patent; Will Not List Two Others

AstraZeneca is expected to make a decision on whether to list an aaiPharma patent covering omeprazole in the "Orange Book" by the end of the month.

AaiPharma Fast-Acting Diclofenac NDA Filing Planned For 2002

AaiPharma plans to submit an NDA by the end of 2002 for its rapidly absorbed diclofenac, claiming a shorter time-to-peak benefit in acute pain.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By